30 Jun 2023 07:00
e-therapeutics plc
("e-therapeutics" or the "Company")
Investor Presentation
London, UK, 30 June 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, reminds interested investors that it will hold an online live investor presentation titled "AI's Game-Changing Impact on Drug Discovery" via Investor Meet Company on 3 July 2023 at 11:00am BST.
The presentation will be delivered by Ali Mortazavi, CEO of e-therapeutics plc, and will run for approximately 40 minutes. After the presentation there will be an opportunity for Q&A.
The presentation will be open to all existing and prospective shareholders. New potential investors will need to sign up to Investor Meet Company for free and add to meet e-therapeutics plc via:
https://www.investormeetcompany.com/e-therapeutics-plc/register-investor
Investors who already follow e-therapeutics plc on the Investor Meet Company platform will automatically be invited.
Any questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation.
Enquiries:
e-therapeutics plc |
|
Ali Mortazavi, CEO Laura Roca-Alonso, COO/CBO
| Tel: +44 (0)20 4551 8888 www.etherapeutics.co.uk |
|
|
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker |
|
Matthew Johnson/Harry Davies-Ball (Corporate Finance) |
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary HepNetTM platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetTM. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicTM constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.